Amie Brogden
Family · Lubbock, TXNPI 1922470921
Payments from drug & device makers
Across 77 payments — averaging $18.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$322
- GSK$195
- AstraZeneca$150
- Exeltis, USA Inc.$135
- Novo Nordisk$134
- AbbVie$110
- plus $409 from 13 others
What the payments were for
- Food & beverage$1,37094%
- Education$856%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 19 | $322 |
| GSK | 12 | $195 |
| AstraZeneca | 9 | $150 |
| Exeltis, USA Inc. | 2 | $135 |
| Novo Nordisk | 8 | $134 |
| AbbVie | 6 | $110 |
| Astellas Pharma US Inc | 2 | $110 |
| Mylan Specialty L.p. | 3 | $56 |
| Nabriva Therapeutics, PLC | 3 | $52 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $42 |
| Dexcom, Inc. | 1 | $19 |
| Exact Sciences | 1 | $19 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $18 |
| Merck | 1 | $18 |
| Organon | 2 | $17 |
| Tris Pharma Inc | 1 | $16 |
| Ironshore Pharmaceuticals Inc. | 1 | $16 |
| Sanofi Pasteur Inc. | 1 | $15 |
| Genentech USA, Inc. | 1 | $12 |
How this compares
$1,455 in reported general payments places this provider in the 75th percentile of 15,456 family providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 84 | $95,318 |
| OzempicSemaglutide | 41 | $41,414 |
| JardianceEmpagliflozin | 37 | $37,819 |
| JanuviaSitagliptin Phosphate | 23 | $27,312 |
| FarxigaDapagliflozin Propanediol | 32 | $24,803 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 19 | $16,166 |
| RybelsusSemaglutide | 13 | $16,078 |
| TrulicityDulaglutide | 11 | $11,562 |
| LinzessLinaclotide | 12 | $8,794 |
| Tresiba Flextouch U-100Insulin Degludec | 16 | $7,754 |
| Tresiba Flextouch U-200Insulin Degludec | 11 | $7,157 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 59 | $6,800 |
| Dexlansoprazole DrDexlansoprazole | 12 | $5,300 |
| Levothyroxine Sodium | 330 | $3,035 |
| Varenicline Tartrate | 14 | $2,778 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $322 | $106,88195 claims |
| Novo NordiskOzempic, Rybelsus | $134 | $57,49254 claims |
| MerckJanuvia | $18 | $27,31223 claims |
| AstraZenecaFarxiga | $150 | $24,80332 claims |
| GSKTrelegy Ellipta | $195 | $16,16619 claims |
| AbbVieLinzess, Synthroid | $110 | $9,75634 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 15,456 family providers in Texas.
Other family in Lubbock
- Lashonda CraneHouston$3.4M
- David WeirDallas$959K
- Luba YammineHouston$479K
- Robin BeachHouston$428K
- Nirupama JeromeAustin$418K
- April LopezMcAllen$417K
- Linda MercadoHouston$211K
- Sarah AguilarHouston$199K
- Sie ThomasDallas$197K
- Anna CastroSan Antonio$184K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.